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ABSTRACT
The safety of vaccines is a critical factor in maintaining public trust in national vaccination programs.
Vaccines are recommended for children, adults and elderly subjects and have to meet higher safety
standards, since they are administered to healthy subjects, mainly healthy children. Although vaccines are
strictly monitored before authorization, the possibility of adverse events and/or rare adverse events
cannot be totally eliminated.
Two main types of inﬂuenza vaccines are currently available: parenteral inactivated inﬂuenza vaccines
and intranasal live attenuated vaccines. Both display a good safety proﬁle in adults and children. However,
they can cause adverse events and/or rare adverse events, some of which are more prevalent in children,
while others with a higher prevalence in adults.
The aim of this review is to provide an overview of inﬂuenza vaccine safety according to target groups,
vaccine types and production methods.
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Introduction
Vaccination is the most effective method of controlling sea-
sonal inﬂuenza infections and the most important strategy for
preventing possible pandemic events.1 Inﬂuenza vaccines are
recommended for children, adults and elderly subjects.2 Since
vaccines are mainly administered to healthy people, they need
to comply with a higher safety standard. In addition, as they
are used to immunize a considerable part of the population,
rare adverse events (AEs) may affect a signiﬁcant number of
individuals.3,4
A “vaccine AE” or an “AE following immunization” is
deﬁned as “any untoward medical occurrence which occurs dur-
ing administration of a vaccine or follows immunization and
which does not necessarily have a causal relationship with the
use of the vaccine. The adverse event may be any unfavorable or
unintended sign, an abnormal laboratory ﬁnding, a symptom or
a disease”.5 AEs also include those events associated with vacci-
nation errors and reactions correlated with anxiety and product
quality defect.
The terms “adverse drug reaction” and “adverse vaccine
reaction or effect” are both used to indicate that the develop-
ment of the AE has a causal relationship with the medicinal
product, as indicated by consistent scientiﬁc evidence.6 The
identiﬁcation of potential serious adverse reactions during clin-
ical trials can evoke signiﬁcant changes in the manufacturing
process, especially if these reactions are fatal or life-threatening;
in such cases, regulators should be promptly informed. It is rec-
ommended that the old term “side effects”, which was used to
indicate both favorable (positive) and unfavorable (negative)
effects, should no longer be used, or at least not as a synonym
for the terms “adverse event” or “adverse reaction”.7 Moreover,
the terms “severe” and “serious” do not have the same meaning.
Indeed, whereas the former is usually used to indicate the sever-
ity of a particular event, which may have minimal medical
importance, the latter identiﬁes the outcome of the patient or
the measures required to deal with the reactions that threaten
the patient’s life or functions; these serious reactions are subject
to obligatory reporting.7
Before a vaccine is licensed, its safety is evaluated in different
phases of clinical trials; it subsequently undergoes post-licen-
sure surveillance.8
Vaccine safety may differ according to the target group, the
genetic predisposition of the population and the type of vaccine.9
Although vaccines are strictly monitored before authoriza-
tion, the possibility of AEs due to annual changes in vaccine
formulations, vaccine administration patterns, environmental
factors or genetic factors of the host cannot be totally elimi-
nated. Consequently, annual post-licensure vaccine safety sur-
veillance is fundamental.10 With regard to extremely rare
events (1 case every 10,000 vaccinations),11 the relatively low
number of cases available for analysis constitutes a study limita-
tion. If no event of concern is registered in a study (i.e. a zero
numerator is reported), it is necessary to conduct further inves-
tigations. Indeed, a zero numerator does not mean the absence
of risk.12 In the case of a vaccine, AEs can only be reliably iden-
tiﬁed after larger populations have been vaccinated. For this
reason, post-marketing surveillance is fundamental. Recently,
an increased incidence of narcolepsy was reported in six Euro-
pean countries following vaccination with Pandemrix against
pandemic inﬂuenza A virus, A(H1N1)pdm09 (“swine ﬂu”),
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during the winter 2009–2010 (see below). The recent systematic
review and meta-analysis conducted by Sarkanen and coll.13 in
order to investigate the incidence of narcolepsy related to
H1N1 vaccination revealed that Pandemrix was the only vac-
cine associated with an increased risk. The relative risk of nar-
colepsy was 5- to 14-fold higher in children/adolescents and
2- to 7-fold higher in adults in the ﬁrst year following immuni-
zation. Furthermore, investigations conducted in Finland and
Sweden seemed to demonstrate that the risk of narcolepsy
extended into the second year after vaccination, although fur-
ther data are necessary to conﬁrm this hypothesis. In addition
to post-marketing surveillance, enhanced safety surveillance
(ESS) is required by the European Medicines Agency (EMA)
for all seasonal inﬂuenza vaccines, in order to improve the
rapid detection of clinically signiﬁcant changes in the safety
proﬁle of ﬂu vaccines.14,15 It is recommended that ESS is
included in routine pharmacovigilance activities if the vaccine
is used for the ﬁrst time and is administered to all age-groups
(e.g. subjects aged 6 months to 5 years, 6 to 12 years, 13 to
18 years,  18 years-65 years and > 65 years).14
In Europe, vaccine safety is monitored by the Vaccine
Adverse Event Surveillance and Communication (VAESCO)
consortium, and in the United States by the Centers for
Disease Control and Prevention (CDC) through the routine
use of two surveillance systems: the Vaccine Adverse Event
Reporting System (VAERS) and the Vaccine Safety Datalink
(VSD).16
In addition to national surveillance organizations, the World
Health Organization (WHO) has established a global system
for international drug monitoring – the Uppsala Monitoring
Center (UMC) and the Global Advisory Committee on Vaccine
Safety (GACVS) – in order to address vaccine safety issues of
potential global importance in a scientiﬁcally accurate man-
ner.3,4,17 The surveillance of inﬂuenza vaccine safety in terms of
post-marketing adverse drug events is usually prompted by
spontaneous reporting. While North America and Europe have
the most advanced information systems for the assessment of
drug safety upon licensing and population coverage, Asian
countries are making good progress.18
The aim of this review is to provide an overview of vaccine
safety according to target groups, vaccine types and production
methods.9
Vaccine types and production methods
The safety of vaccines is a critical factor in maintaining public
trust in national vaccination programs. This is especially true
of inﬂuenza vaccines, the composition of which needs to be
evaluated twice a year in order to ensure antigenic matching
between the viral strain contained in the vaccine and the circu-
lating strain.19 Two main types of inﬂuenza vaccines are cur-
rently available and are administered by different routes:
parenteral inactivated inﬂuenza vaccines (IIVs) and intranasal
live attenuated inﬂuenza vaccines (LAIVs). The former have
been used for more than 50 years, are licensed for use in sub-
jects aged 6 months and display a good safety proﬁle; the lat-
ter are licensed in Europe for children from 2–17 years of age
and induce a broader immune response involving both local
and systemic antibody and T-cell responses.20
Inactivated Inﬂuenza Vaccines
IIVs have been manufactured and used since 1940, and are the
most common inﬂuenza vaccines. Until 2015, vaccine producers
were required by EMA committee to perform annual clinical tri-
als in order to evaluate both immunogenicity and safety for the
updating of seasonal annual IIVs.21 Clinical trials are no longer
required for lineage changes of licensed IIVs.22 Inactivated vac-
cines have an excellent safety proﬁle, and are recommended for
children of 6 months of age, the elderly, asthmatics and those
individuals with other high-risk conditions.
Trivalent Inﬂuenza Vaccines
Trivalent inﬂuenza vaccines (TIVs) (containing A/H1N1, A/
H3N2 and one B lineage) have been manufactured since 1978,
replacing the bivalent inactivated inﬂuenza vaccines that had
been widely used since 1944 (Table 1).23
During the 1990–2006 and 2008–2009 inﬂuenza seasons,
Muhammad et al.24 investigated possible new or unexpected AEs
following TIV administration to children aged 2 to 17 years and 5
to 17 years, respectively. From 1990 to 2006, 2,054 cases of vaccine
AEs were reported, peaking in the 2003–2004 inﬂuenza season,
whereas 506 were reported in 2008–2009. Higher proportions of
medication errors and Guillain-Barre Syndrome (GBS) were
observed, although the latter could not be causally correlated with
vaccination. Among 201 reports regarding medication errors, 94%
did not cause AEs other than the medication error itself.
TIV vaccination is recommended for children older than 6
months and between 6 and 59 months with a predisposition to
severe inﬂuenza in Australia and Western Australia, respectively.25
In 2010 in Australia, an increase in febrile convulsions (FCs) was
observed after TIV immunization; however, this involved only one
brand, produced by bioCSL (Fluvax and Fluvax Junior). Subse-
quently, Li-Kim-Moy and coll.26 reviewed the safety of TIV admin-
istration. Speciﬁcally, they investigated the rates of fever, FCs and
serious AEs reported in both unpublished and published clinical tri-
als conducted on children during the period 2005–2012. The inci-
dence of fever or AEs caused by TIV was low, whereas higher fever
rates were correlated with bioCSL inﬂuenza vaccines in young chil-
dren. However, it was not possible to attribute this to the TIV strain
composition. This study highlights the necessity to strictly monitor
seasonal inﬂuenza vaccine safety and to report post-administration
data accurately.26 A recent study conducted by Esposito et al.27
investigated the tolerability and safety of TIV in overweight and
obese children between 3 and 14 years old, since obesity is an
important risk factor for infections that are facilitated by respiratory
diseases. In overweight/obese children, the antibody response upon
TIV vaccination was similar to or slightly greater than that observed
in normal-weight subjects of similar age, and this situation persisted
for at least 4 months after vaccine administration. The incidence of
local and systemic reactions was comparable between the groups,
Table 1. Vaccine types and route of administration.
Vaccine types Route of administration
TIV Parenteral Intradermal
QIV Parenteral
LAIV Intranasally
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and no serious AE was observed, conﬁrming that inﬂuenza vaccines
have a good safety proﬁle even in overweight/obese children.27
Quadrivalent Inﬂuenza Vaccines
In addition to the 3 strains present in TIV, namely H1N1 and
H3N2 inﬂuenza A subtypes and inﬂuenza B, the formulation of
Quadrivalent Inﬂuenza Vaccines (QIVs) contains two addi-
tional inﬂuenza B lineages, Yamagata and Victoria, which have
been spreading since 1985 and have reduced the efﬁcacy of
TIV.28 QIVs should enhance protection against inﬂuenza B by
avoiding the possibility of a B strain mismatch. The ﬁrst quad-
rivalent LAIV was licensed in 2012 and, after several QIV for-
mulations had been tested, it entered the market (Table 1).29
The WHO recommended both B lineages for inclusion in the
2012–2013 inﬂuenza seasonal vaccine in the Northern hemi-
sphere. In the US, 4 QIVs have recently been approved: the three
inactivated vaccines FluarixTM, FluLavalTM (both GlaxoSmithK-
line Vaccines) and Fluzone (Sanoﬁ Pasteur) and the LAIV
FluMist (MedImmune).30 In a phase-II multi-center study con-
ducted on healthy adults aged18 years, Greenberg et al.31 com-
pared the safety and immunogenicity of a QIV whose
formulation contained two inﬂuenza B strains versus licensed
TIVs containing either a Victoria B-lineage strain (2009-2010
TIV) or a Yamagata B-lineage strain (2008-2009 TIV). Seropro-
tection, seroconversion and AEs were comparable in all groups.
Pepin and coll.32 investigated the immunogenicity and safety
of a prototype inactivated QIV immunization (containing
A/California/07/2009 (H1N1), A/Victoria/210/2009 (H3N2), B/
Brisbane/60/2008 (Victoria lineage) and B/Florida/04/2006
(Yamagata lineage) strains) in comparison with both a licensed
2011–2012 TIV (containing A/California/07/2009 (H1N1),
A/Victoria/210/2009 (H3N2) and B/Brisbane/60/2008 (Victoria
lineage) strains) and an investigational TIV (containing the alter-
native B strain lineage B/Florida/04/2006 (Yamagata lineage), the
A/California/07/2009 (H1N1) and A/Victoria/210/2009 (H3N2)
strains). They conducted a phase-III, randomized, active-con-
trolled, multi-center trial involving 1568 adults during the 2011/
2012 inﬂuenza season. All groups had similar pre-vaccination
HAI antibody titers and showed an increase following immuniza-
tion. Antibody responses following QIV administration were not
inferior to those elicited by the TIVs for all the matched strains.
Moreover, the QIV was able to induce higher antibody responses
against the B strains not contained in the TIVs. All the strains
contained in the QIV met the EMA criteria for both age-groups
of subjects (18-60 years and > 60 years). With regard to the
TIVs, however, only the A and matched B strains met all EMA
criteria; the unmatched B strains did not. The fact that all three
vaccines evoked higher responses and response rates in the youn-
ger adults than in the elderly adults is in agreement with the liter-
ature, and is due to the waning responsiveness of the elderly
immune system and to other aging- factors.33,34 A meta-regres-
sion study conducted by Beyer and coll.35 further conﬁrmed that
the beneﬁt of QIV depends on age. Indeed, they observed that
the impact of B lineage mismatch was negatively associated with
pre-seasonal immunity. Infants and children beneﬁted most
from QIV since they had not yet been exposed to inﬂuenza B;
accordingly, vaccine effectiveness declined as pre-seasonal
immunity increased. QIV administration may therefore provide
less signiﬁcant protection in the elderly than in the young in the
case of lineage mismatch.
The safety and reactogenicity of QIV have proved similar to
those of seasonal inﬂuenza vaccines, as demonstrated by
Tinoco et al.36 The most common adverse reactions were pain
at the injection site, headache and myalgia, all of which disap-
peared within 3 days of vaccination. No serious AE or death
were registered.
Similar results regarding the safety of the ﬁrst QIV intro-
duced in Australia were reported by Regan et al.37 in a sample
of 1,685 healthcare providers (HCPs). Although 7 days after
immunization no AE was observed in either QIV- or TIV-vac-
cinated subjects, a slightly but signiﬁcantly higher percentage
of QIV-immunized than TIV-immunized HCPs reported pain
or swelling at the injection site. That study conﬁrmed the safety
of QIV, since its reactogenicity was similar to that of TIV. The
meta-analysis recently conducted by Moa and coll.38 also
showed no signiﬁcant differences between the safety proﬁles
of QIV and TIV, except for a slightly higher rate of injection-
site pain following QIV immunization, which may have been
due to the higher dose (60 versus 45 mcg), in agreement with
the results of the study by Regan.37
It has been suggested that differences in production methods
yielding vaccines of different composition – in addition to the
presence of a further antigen in QIV – may be responsible for
the different frequency of AEs.37 However, although QIV eli-
cited slightly more local reactions (injection-site pain) than
TIV, the potential beneﬁt of QIV in protecting the population
from infection is considered to be greater.38
The safety and reactogenicity proﬁle of inactivated QIV in
children aged 18–47 months was evaluated by Rodriguez
Weber and coll.39 in a phase-II double-blind study. Reactoge-
nicity was investigated since QIV contains 60 mg of antigen
compared with 45 mg in TIV. Serious AEs were monitored for
6 months after immunization. The reactogenicity and safety
proﬁles of QIV were similar to those observed for TIV.
An investigation on the VAERS reports following vaccina-
tion with IIV4 and trivalent IIV3 from 7/1/2013 to 5/31/2015
was conducted by Haber et al.,40 who reported similar safety
proﬁles between the two vaccines. This observation was in
agreement with the data obtained from pre-licensure studies of
IIV4. Most of the AEs reported were non-serious. Among the
most frequent AEs in persons aged between 6 months and
17 years, were fever, injection-site swelling and erythema,
whereas pain in the extremities and injection-site pain were
most frequent in individuals aged 18–64 years. The most com-
mon non-lethal serious events were GBS, seizures, injection-
site reactions and anaphylaxis.
Live attenuated inﬂuenza vaccines
LAIVs have been used in Russia for decades, and were licensed
in the US in 2003 for healthy subjects aged 2–49 years41 and in
Europe in 2012 for healthy children aged 2–17 years. They are
able to induce a stronger immune response than IIV by mim-
icking natural infection (see below).20 Since they are adminis-
tered intranasally, several adaptive immune responses, such as
serum antibodies, mucosal and cell-mediated immunity are
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induced.42 The evoked immune response directed towards
neuraminidase and hemagglutinin glycoproteins is similar to
that elicited by the process of naturally occurring infection.43,44
The fact that a higher incidence of infections involving the
lower airways was not observed supports the notion that the
virus is unable to replicate and induce pathology in the respira-
tory tract.45,46 Consequently, protection against the virus con-
tained in the vaccine formulation and mismatched strains is
induced by LAIVs.47 The development of severe inﬂuenza fol-
lowing LAIV immunization is prevented, since the vaccine con-
tains a cold-adapted inﬂuenza virus that is unable to replicate
in temperature conditions >37.8C.43,44 LAIV is not recom-
mended in elderly or immunosuppressed subjects or in those
who are caring for persons in whom severe inﬂuenza disease
carries high risk. LAIVs are not recommended for children
< 2 years of age, as, in early investigations, the administration
of LAIVs to this age-group promoted the onset of wheezing.
Furthermore, LAIVs are contraindicated in severe asthmatics
currently on oral or high-dose inhaled glucocorticosteriods or
who have active wheezing.47,48
Concomitant immunization with other usual childhood vac-
cines has been shown not to inﬂuence the immune response
induced by LAIV in healthy young children.49
Furthermore, LAIVs proved to be more effective than TIV
in reducing the incidence of inﬂuenza illness in two open-label
studies conducted on children aged 6–71 months affected by
recurrent respiratory tract illnesses and in children and adoles-
cents with asthma aged 6–17 years.49 LAIV displays a good
safety proﬁle, comparable to that of TIV.46,50-53
LAIV vaccinees show the presence of the vaccine virus, but
the risk of transmitting the virus to household members is mar-
ginal, ranging from 0.58% to 2.87%. In only one case has the
transmission of LAIV virus to a placebo recipient been
reported. In that case, however, transmission did not induce
the disease.54 It has been observed that, in children aged 9–36
months, the presence of the virus is highest 3–5 days after vac-
cination, reaching up to 80%, whereas it is lower in adults
affected by HIV (1.8%).55 Furthermore, not only do LAIVs
elicit direct protection in vaccinated subjects, they also promote
indirect protection by reducing the transmission of the inﬂu-
enza virusamong subjects belonging to clinical risk groups.56
LAIVs have been reported to cause adverse effects in 15% of
cases. However, these are not serious: nasal congestion, runny
nose and slight fever in adolescents, and sore throat in adults.
With the exception of fever, which has been reported on the
day after vaccination, the other symptoms occur 2–3 or 8–
9 days after LAIV administration.45 LAIVs have been reported
to cause slightly more troublesome moderate adverse effects
than TIV, though the incidence of these is low. The difference
was signiﬁcantly higher following the ﬁrst dose, but disap-
peared after the second administration48 and was reduced fol-
lowing the subsequent annual vaccinations. Although one of
the most frequent side effects in young children was wheezing,
no difference in severity, length of hospitalization or treatment
was observed.45,48 Furthermore, asthma episodes occurring in
LAIV vaccinees showed a 4-fold increase in comparison with
controls in the 42 days after vaccination.45
Severe consequences have rarely been reported, and have
displayed a similar frequency after LAIV, TIV and placebo; no
association with vaccine administration has been proved.
Recently, McNaughton’s group investigated the incidence of
adverse effects of interest (AEIs) in children and adolescents
upon immunization with nasal QLAIV (Fluenz Tetra, Astra
Zeneca) in the same inﬂuenza season in England. They
reported nasal congestion, cough and malaise among the most
frequent AEIs. No serious AE, hospitalization or death was
reported during the investigation.57
Since a higher frequency of fever has been reported after
LAIV than after IIV vaccine administration, a recent prospec-
tive observational study conducted by Stockwell’s group58
investigated the frequency of fever following immunization of
young children with IIV in 3 community clinics in New York
City. A low frequency of fever was found and no difference
between the vaccines evaluated was observed during the 2013–
2014 inﬂuenza season.58
The studies conducted by Carr et al.59 and King et al.60 con-
ﬁrmed the safety of LAIV in children affected by cancer and in
HIV-infected adults, respectively.
However, discordant data on the efﬁcacy of LAIV have
emerged between the US and Europe.61 Speciﬁcally, owing to
ineffectiveness during the previous three seasons (2013–2014,
2014–2015 and 2015–2016),62 the use of LAIV was not recom-
mended in the US during the 2016–2017 inﬂuenza season, and
the recommendation not to use LAIV has been renewed for the
2017–2018 ﬂu season.63 Conversely, many other health authori-
ties, including those in the UK and Canada, consider the efﬁ-
cacy of LAIVs to be adequate. Several factors have been
hypothesized to have played a role in the diminished vaccine
effectiveness, including methodological issues in the studies.64
LAIV in egg-allergic individuals, asthmatic subjects
or children with recurrent wheezing
Until recently, few safety data regarding LAIV administration
in egg-allergic young children were available, although egg
allergy is relatively common, affecting between 2–6% of pre-
school children.65
In the US, the prevalence of asthma66,67 and egg allergy68 has
prompted vaccine manufacturers to tackle the problem of
immunizing egg-allergic patients in whom vaccination with
egg-containing inﬂuenza vaccine is recommended.
In the 1970s, egg-allergic patients had to undergo skin test-
ing with the inﬂuenza vaccine69-71; if the result was negative,
they could be safely immunized, otherwise vaccination was not
recommended. However, a subsequent study conducted by
Murphy and Strunk72 found that inﬂuenza vaccination was safe
even in the event of a positive skin-test result if a protocol of
multiple, graded injections was implemented, whereas Zeiger73
suggested that inﬂuenza vaccine skin tests (prick and intrader-
mal) should be carried out before vaccine administration in
individuals with a history of adverse reactions to eggs and posi-
tive skin-test results. A single dose could be administered if the
inﬂuenza vaccine skin-test results were negative, while a 2-dose
graded or desensitization protocol should be implemented if
they were positive.73,74 The safety of administering the inﬂu-
enza vaccine in a graded 2-dose fashion to egg-allergic children
without performing the vaccine skin test was investigated by
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Chung and coll.75 in a retrospective chart-review study, which
suggested that the skin test could safely be omitted.
A recent investigation conducted by Turner et al.65 found a
low risk of systemic allergic reactions following LAIV immuniza-
tion in subjects aged 2–18 years during the inﬂuenza season
2014–2015 in the UK; 35% of the children had a history of ana-
phylaxis to eggs. Immediate AEs following LAIV immunization
were mild and self-limiting; these were: contact/localized urti-
caria, rhinitis and oropharyngeal itching. Delayed adverse effects
potentially correlated with LAIV were lower respiratory tract
symptoms, which occurred within 72 hours of vaccination. This
higher incidence was reported in young children, but it did not
reach statistical signiﬁcance. Delayed events were not associated
to any risk factor. In addition, the vaccine was well tolerated by
asthmatic subjects and those under 5 years of age who were
affected by recurrent wheezing65; this ﬁnding is in agreement
with those of other studies.46,48,50,76-78 However, certain guide-
lines in North America do not currently recommend its use in
subjects of this age who have had an episode of wheezing in the
previous year.79
Pandemic inﬂuenza vaccines
Any pandemic inﬂuenza vaccine may have an incompletely
described safety proﬁle.80 A correlation between inﬂuenza vac-
cines and GBS has been reported by several studies – in 197681
and in 1992–199481-83 – and by three meta-analyses.84-86 The
authors of these last studies reported a 2–3-fold higher risk of
GBS in subjects vaccinated with either adjuvanted or non-adju-
vanted A(H1N1)pdm09 vaccines in comparison with unvacci-
nated subjects. However, contrasting results have also been
reported.87-90 The potential adverse effect of A(H1N1)pdm09
monovalent or trivalent vaccination was also assessed by
Alcalde-Cabero and coll.,91 but no association was found.
Recent epidemiological investigations have conﬁrmed the
association between an AS03-adjuvanted pandemic inﬂuenza
vaccine (Pandemrix, GlaxoSmithKline Biologicals, Germany)
and the onset of narcolepsy in children and adolescents.92 The
novel circulating A(H1N1) inﬂuenza virus was identiﬁed in
April 2009 and quickly spread worldwide in June 2009. Mil-
lions of A(H1N1) pandemic vaccine doses were produced
within a narrow time-window (from April 2009 until Novem-
ber of the same year). One year after the European AS03-adju-
vanted A(H1N1) pandemic vaccine was authorized in Europe,
a higher number of narcolepsy cases was observed in Sweden
and Finland (9.0/100,000 incidence in vaccinees versus 0.7 in
unvaccinated subjects),92-95 and also in other countries.11,96 It
was hypothesized that a peptide located on a surface-exposed
region of inﬂuenza nucleoprotein A was characterized by pro-
tein residues similar to the ﬁrst extracellular domain of hypo-
cretin (HCRT) receptor 2. In accordance with this hypothesis,
a higher frequency of antibodies to HCRT receptor 2 was found
in sera from narcoleptic Finnish patients immunized with the
European AS03-adjuvanted vaccine Pandemrix92 than in
unvaccinated subjects. Furthermore, a cross-reaction between
HCRT receptor 2 and inﬂuenza nucleoprotein was described.
No persistent antibody response to nucleoprotein was detected
in sera from non-narcoleptic subjects vaccinated with Focetria
(a vaccine differently produced), which contained 72.7% less
inﬂuenza nucleoprotein. Thus, differences in vaccine nucleo-
protein content and the respective immune response could
explain the correlation between narcolepsy and Pandemrix.97
A recent study98 investigated the annual frequency of ana-
phylaxis following immunization, a rare AE which can be life-
threatening and causes hospitalization within 48 hours after
immunization. The study was conducted on subjects younger
than 18 years in Germany between June 2008 and May 2010.
Of the 22 cases of anaphylaxis evaluated, 8 were due to the
administration of AS03-adjuvanted A/H1N1 pandemic inﬂu-
enza vaccine. This vaccine was associated with a higher risk of
anaphylaxis than other vaccines, with an incidence of 11.8 of
cases per 1,000,000 doses administered.
Age-groups
While inﬂuenza viruses infect all age-groups, children and
adults over the age of 65 years are most at risk. Vaccination is
recommended for these age-groups, for pregnant women, for
subjects with high-risk conditions due to complications of
inﬂuenza and for those with chronic medical conditions (meta-
bolic, cardiac, pulmonary or kidney diseases, and immunocom-
promised patients). The same recommendation is generally
extended to nurses and healthcare workers.99,100
Most inﬂuenza vaccines are safe in adults and children.
However, they can sometimes cause AEs. According to the age-
group, AEs may include fever, vomiting, nausea, headache, irri-
tability, injection site reaction and rash.9,100
Children
Infants and children (particularly those younger than 5 years
old) are especially susceptible to inﬂuenza infection and its
complications, such as pneumonia. These subjects play a pri-
mary role in the transmission of inﬂuenza viruses, since they
acquire and release greater amounts of virus than adults.101-103
In 2003 in the US, inﬂuenza vaccination was ofﬁcially rec-
ommended for healthy children aged 6–23 months, and in
2008 “universal” vaccination of all subjects over 6 months of
age was recommended.102,104
The scenario is different in Europe, where, despite several rec-
ommendations by international experts and advisory groups,
pediatric vaccination has not reached a satisfactory level.105
Worldwide, TIVs are currently the only injectable prepara-
tions authorized for pediatric use in children above 6 months
of age.101
Several studies have evaluated the safety of TIVs in healthy
children, and have found a good safety proﬁle with no serious
AEs.106-109 The most common solicited local reactions are pain
and redness at the injection site, while the most common soli-
cited systemic reaction is irritability, followed by malaise and
headache (Table 2).107-110
In the USA, the recommended dose for children below
3 years of age is half of the adult dose. However, several studies
have provided evidence that the administration of a full dose is
safe in children and does not increase reactogenicity.107,108,110
More speciﬁcally, local reactions are more common in toddlers
than in infants, and in full-dose vaccinees, though the differen-
ces are not signiﬁcant.108 As stated above, the most commonly
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reported systemic reaction is irritability, whereas the most com-
mon local reactions are redness and tenderness in the ﬁrst
3 days after vaccination.107,108 Concerning other local reactions,
swelling and induration more frequently occur after a full dose,
but are less commonly reported.108
In addition, cell-derived inﬂuenza vaccines are also well-tol-
erated and have a good safety proﬁle – comparable to that of
egg-derived inﬂuenza vaccines – in children.111,112 Pain at the
injection site is the most common local reaction, while
the most commonly reported systemic reactions are: malaise in
the 4-8-year-old cohort and headache among 9-17-year-olds
(Table 1).112
Esposito et al.113 evaluated the safety and reactogenicity of
intradermal (ID) inﬂuenza vaccine, an alternative route of
injection to the traditional intramuscular (IM) modality, in
children older than 3 years. Although local reactions were
more common in the cohort of ID vaccinees than in the IM
vaccine group, they were transitory and did not become more
frequent as the vaccine dose increased.
However, the efﬁcacy of TIVs is not completely satisfactory
in children. For this reason, adjuvanted vaccines have been
developed in order to improve the immune response. Clinical
studies have demonstrated the great advantage of these vac-
cines, which are able to induce an enhanced immune response
in children, even against B strains, in the case of low pre-immu-
nization titers and mismatching viruses.1 Overall, adjuvanted
vaccines induce slightly higher local and systemic reactogenic-
ity than TIVs; however, the reactions are mild and transient,
and there is no increase in unsolicited AEs.114-118 In children
younger than 36 months, the most commonly reported local
reactions are injection-site pain, tenderness and erythema
(Table 2),114,115,117 while the most common systemic reactions
are irritability, diarrhea and crying (Table 2).114,117 In older
children injection-site pain, erythema and induration are the
most common local reactions, while systemic reactions are:
fatigue, chills, headache, fever and myalgia (Table 2).114,116,117
Fever displays a higher incidence after the second dose.116
Overall, children older than 36 months display a higher inci-
dence of solicited reactions than younger children.114
Recently, seasonal inactivated QIV containing both the Vic-
toria and Yamagata lineages of the B virus have been marketed;
these have shown a superior antibody response against the
additional B strain and immunogenicity comparable to the tra-
ditional TIVs.1,119 In children aged 6–35 months, their safety
proﬁle is acceptable and similar to that of TIVs, and their reac-
togenicity seems not to be excessive on increasing the amount
of inﬂuenza antigen.120,121
The other licensed vaccine is the LAIV, which is adminis-
tered intranasally to persons aged 2–49 years in the USA,
Europe, India and Russia. The advantages of the LAIV vaccine
are its ability to mimic the natural pathway of infection, to
induce a broader humoral and cellular response than TIV and
to provide protection against both well-matched and antigeni-
cally drifted strains.1 The most frequently reported reaction is
nasal congestion57,122 together with low-grade fever and
decreased activity (Table 2).122 These symptoms did not occur
after the second dose.122 While no serious AE has been
reported,122-124 McNaughton et al.57 reported asthma in a large
number of study participants, which suggests that quadrivalent
LAIV should not be administered to children or adolescents
with severe asthma or active wheezing.
Vaccination remains the most effective strategy for prepar-
ing for seasonal infections and for a possible pandemic. The
WHO guidelines state that, whenever possible, the safety of
pandemic vaccines should be evaluated before the pandemic.
However, the safety proﬁle of a pandemic inﬂuenza vaccine
may not be completely investigated.80,125
Most of the pandemic vaccines against the H1N1 pdm09
inﬂuenza virus have been evaluated. Overall, they have shown a
clinically acceptable safety proﬁle, without any serious AEs or
potentially immune-mediated diseases.126-128 As for the other
vaccines, the most commonly reported local reaction is injection-
site pain, together with redness and swelling (Table 2).127-131 The
most frequent systemic reactions are malaise, fatigue and myalgia
(Table 2).127,132 Plennevaux et al.131 reported that headache,
myalgia and malaise were more common in children older than
24 months, while irritability, abnormal crying, loss of appetite
and drowsiness occurred more frequently in children younger
than 24 months. The most common unsolicited AEs are upper
respiratory tract infection126,127 and nasopharyngitis.127 Adju-
vanted and non-adjuvanted H5N1 vaccines are safe and well tol-
erated, though Diez-Domingo et al.133 reported one potential
immune-mediated disease (autoimmune hepatitis) related to
vaccination.
Adults and the elderly
Inﬂuenza vaccination is generally recommended for the elderly,
as they are at risk of, and more vulnerable to, inﬂuenza compli-
cations.134 The European guidelines do not include other
groups among those recommended for vaccination, though
vaccination has been strongly suggested for caregivers and
healthcare workers.135 However, inﬂuenza disease in adults car-
ries a signiﬁcant societal cost in terms of absence from work
and lost productivity.136,137
Several studies have evaluated the safety proﬁle of egg/cell-
derived, adjuvanted/non-adjuvanted inﬂuenza TIV and QIV in
adults and elderly subjects. Overall, the vaccines showed a
Table 2. Most common local and systemic reactions in children.
Children
Vaccine Local reaction Systemic Reaction
TIV Pain Irritability
Redness Malaise
Tenderness Headache
adjuvanted TIV Pain Irritability
Tenderness Diarrhea
Erythema Crying
Induration Fatigue
Chills
Headache
Fever
Myalgia
LAIV Nasal congestion Fever
Decreased activity
Pandemic Pain Malaise
Redness Fatigue
Swelling Myalgia
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robust safety proﬁle and acceptable reactogenicity. Injection-
site pain is the most frequently reported local symptom
(Table 3).31,136,138-143 The most frequent systemic reactions in
both adults and the elderly are fatigue, headache and myalgia
(Table 3).31,136,140-146 Only one study reported fever as the most
common solicited reaction.139 Rates of solicited local and
systemic reactions are higher in adults than in the
elderly31,139,141,142,145,147,148 and in females than in males.145
Unsolicited AEs are nasopharyngitis and cough.31,136,138,146
Overall, no serious AEs or deaths related to inﬂuenza vaccina-
tion are reported31,142,143,145,146,149 with the exception of two
studies. The ﬁrst of these136 described serious AEs in the QIV
group (myocardial infarction and cerebrovascular accident)
and the TIV group (pneumonia, cerebrovascular accident,
nephrolithiasis and arteriosclerosis). The second138 reported
one death, possibly related to vaccination, and SAEs (bronchi-
tis, asthmatic crisis, chronic obstructive pulmonary disease and
GBS) possibly or probably related to vaccination with TIV,
with and without adjuvant.
The ID vaccines are well tolerated in adults and the elderly
and have not raised safety concerns.137,150 Malaise and head-
ache are reported to be the most frequent systemic reac-
tions137,151 and their proﬁle is similar to that of vaccines
injected via the IM route.152,153 Local reactogenicity is reported
to be higher after ID vaccination than after IM vaccina-
tion137,152,153 even when subjects are re-vaccinated with ID vac-
cine.137 Swelling appears to be more common in the case of ID
vaccination in the previous year.137
LAIV, whether trivalent or quadrivalent, is safe, without any
increased risk after administration.124,154 The vaccine is cur-
rently approved in the USA, Europe, India and Russia for sub-
jects aged 2–49 years. However, it has also been evaluated in
adults and the elderly.155,156 Reactions after LAIV vaccination
include cough, sore throat, runny rose/nasal congestion and
decreased appetite.155,156 No signiﬁcant AEs following LAIV
vaccination have been reported51 with the exception of upper
and lower respiratory tract infections, wheezing, rhinitis and
sneezing.124,156,157
With regard to children, most of the pandemic vaccines,
with or without adjuvant, are against the pandemic H1N1
inﬂuenza virus.158-164 However, pre-pandemic vaccines, such
as those against H5N1, H7N9 and H5N1, including LAIV,
have also been evaluated.165-167 Overall, these vaccines have
displayed good tolerability and satisfactory safety pro-
ﬁles.158,160,162-164 The most common local reaction is injec-
tion-site pain, while systemic events are fever, headache,
malaise, myalgia and fatigue.111,158-161,163,164 After the second
dose, both types of reaction are similar to those seen after the
ﬁrst, or are attenuated.111,161,164
High-risk individuals
Individuals of any age with certain medical conditions are at
increased risk of inﬂuenza-related complications than the gen-
eral population. Vaccination remains the most effective method
of controlling and preventing inﬂuenza infections, and health
authorities have included individuals with chronic medical con-
ditions among those recommended for inﬂuenza vaccina-
tion.168 The only authorized vaccine for this target group is
TIV, as the safety of LAIV has not been established.169 How-
ever, despite the recommendation, vaccination coverage
remains low among high-risk individuals.170
Several studies have evaluated the safety proﬁle of seasonal
and pandemic inﬂuenza vaccines in high-risk individuals and
have shown that vaccines are well tolerated and safe in this tar-
get group.27,152,171-176 However, the conventional vaccines are
reported to induce a poor immune response in high-risk indi-
viduals, and different strategies, such as administration of a
high-dose booster, the use of adjuvants and ID administration,
have been evaluated.173
Standard doses, high doses and booster doses of TIV have
proved safe and well tolerated in high-risk adults, such as
hematopoietic stem cell transplantation patients, individuals
with type 2 diabetes, solid transplant recipients, patients with
multiple myeloma and with Duchenne muscular dystrophy; no
unexpected serious AEs have been recorded.171-173,177,178 Speciﬁ-
cally, the most common local reaction is pain at the injection
site, while the most frequently reported systemic reactions are
myalgia and general malaise (Table 4). No signiﬁcant differences
in local and systemic reactions between high-risk individuals
and control groups have been reported.171,177 Two studies, how-
ever, detected a trend towards a lower incidence of local and sys-
temic reactions in patients with type 2 diabetes after seasonal
vaccination and in those with Duchenne muscular dystrophy
after pandemic vaccination.173,179 There are no safety concerns
regarding the administration of ID vaccines in high-risk individ-
uals, such as HIV-infected adults and immunocompromised
patients. However, local and systemic reactions are higher with
ID than IM formulations.152,172
The safety of seasonal and pandemic inﬂuenza vaccines in
children with underlying medical conditions has been proven,
Table 3. Most common local and systemic reactions in adults and the elderly.
Adult - Elderly
Vaccine Local reaction Systemic Reaction
TIV/QIV Pain Fatigue
adjuvanted-non Myalgia
adjuvanted Headache
LAIV Cough Decreased appetite
Sore throat
Runny rose/nasal congestion
Pandemic Pain Fever
Headache
Malaise
Fatigue
Myalgia
Table 4. Most common local and systemic reactions in high-risk individuals.
High-risk individuals
Vaccine Local reaction Systemic Reaction
TIV Pain Myalaise
Myalgia
Pandemic Pain Fatigue
Tenderness Decreased activity
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and no severe AEs have been reported.27,113,174-176,180,181 The
most common local reactions are pain174,180 and tenderness,
while systemic reactions consisting of fatigue and decreased
general activity have been noted (Table 4).180 Studies have
revealed that standard-dose TIV in overweight and obese chil-
dren and high-dose TIV in children and young adults with can-
cer induce more solicited reactogenicity events, though the
difference is not statistically signiﬁcant.27,175
Conclusions
Inﬂuenza is still a substantial cause of death and suffering dur-
ing the winter months, and imposed a heavy socioeconomic
burden, especially in young subjects and the elderly.134
Although vaccination remains the single best defense against
inﬂuenza and its complications, in many European countries,
vaccination coverage is suboptimal, especially in comparison
with the US. This has serious consequences, such as the evident
excess mortality registered in Italy in elderly subjects who were
not vaccinated against inﬂuenza in 2015182 These data, which
should be conﬁrmed by further investigations, highlight the
necessity to increase rates of immunization through the plan-
ning and implementation of public health interventions. Fur-
thermore, a higher standardization of vaccine strategies has
been observed in the US than in European countries183
Although inﬂuenza vaccines display a good safety proﬁle, a
growing number of people shun vaccination for fear of negative
side effects,92 such as the onset of autoimmune conditions. This
fear, in addition to the public’s misperceptions concerning
adjuvants and their role, have discouraged vaccination not only
against inﬂuenza but also against other infectious diseases,
allowing them to re-emerge.92 A signiﬁcant element in the
overall effectiveness of vaccines is therefore their acceptance by
the public.184
However, not only infective agents are associated with
increased morbidity and mortality, as has previously been
described; it has also been hypothesized that an impaired or inap-
propriate modulation of Toll-like receptors (TLRs), which are
involved in the recognition of invading microorganisms, and in
the defense of the host following natural infections, could exert a
critical role in the development of autoimmune conditions.185
Overall, inﬂuenza vaccines are very safe186 and well tolerated
in most age-groups and formulations. Admittedly, they can
cause AEs and/or rare AEs, some of which are more prevalent in
children, while others are more prevalent in adults. However,
symptoms due to AEs, such as rhinorrhea or congested nose, are
usually transient. Severe allergic reactions to inﬂuenza vaccines
are very rare, being estimated at less than 1 in a million doses.187
Another critical factor is that the currently available inﬂuenza
vaccines are not well suited for use in low and middle-income
countries (LMIC),188 the health systems of which often lack
the resources to implement vaccination adequately. Indeed, the
WHO standards concerning the programmatic suitability
of vaccines are not met by many inﬂuenza vaccines in LMICs. In
these conditions, the priority target group is that of young chil-
dren (< 5 years), whereas other risk groups are considered sec-
ondary targets.189
Further studies of all inﬂuenza vaccines, involving follow-up
periods to bring to light possible increases in hospitalization,
should be conducted on children < 2 years, children from
LMICs or children with prior asthma or wheezing. It is neces-
sary that safety tests be conducted in this age group, for which
data regarding AEs upon LAIV administration are currently
insufﬁcient.
Vaccines have to meet higher safety standards, since they are
administered to healthy people, mainly healthy children.8 The
monitoring of annual inﬂuenza vaccine safety, which is particu-
lar important on account of the annual changes in the viral
antigen composition of the vaccine, constitutes a critical com-
ponent of the inﬂuenza vaccination program. Indeed, not only
does this strategy ensure the safety of vaccines, it can also main-
tain public trust in the national vaccination program. However,
it must be borne in mind that no vaccine is 100% safe in all sub-
jects, that vaccines may potentially cause AEs, and that the
safety proﬁle of a given pandemic inﬂuenza vaccine may not be
completely described.3,80
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